ACRO BIOMEDICAL CO., LTD. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACRO BIOMEDICAL CO., LTD. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $658.5K | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $1.20M | Jul 21, 2023 |
| FY2017 | Sep 30, 2017 | $510.0K | Jan 16, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Jul 18, 2025 |
| FY2023 | Dec 31, 2022 | $140.5K | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $259.5K | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | $159.4K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $12.1K | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | $135.4K | Jan 7, 2020 |
| FY2020 | Dec 31, 2018 | $135.4K | Apr 2, 2021 |
| FY2019 | Sep 30, 2018 | $833.4K | Jan 7, 2020 |
| FY2018 | Sep 30, 2017 | $51.0K | Dec 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($101.1K) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($42.3K) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($8.81M) | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | ($15.87M) | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | ($7.70M) | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | ($117.5K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($75.9K) | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | ($370.7K) | Jan 7, 2020 |
| FY2020 | Dec 31, 2018 | ($75.0K) | Apr 2, 2021 |
| FY2019 | Sep 30, 2018 | $419.7K | Jan 7, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($154.0K) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($38.0K) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($8.80M) | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | ($15.87M) | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | ($7.69M) | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | ($130.5K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($75.4K) | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | ($441.6K) | Jan 7, 2020 |
| FY2020 | Dec 31, 2018 | ($94.2K) | Apr 2, 2021 |
| FY2019 | Sep 30, 2018 | $515.6K | Jan 7, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $4.79M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $10.08M | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $5.29M | Jul 21, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.0K | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $38.0K | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $3.52M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $5.93M | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $2.67M | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | $289.9K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $87.5K | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | $577.0K | Jan 7, 2020 |
| FY2020 | Dec 31, 2018 | $229.6K | Apr 2, 2021 |
| FY2019 | Sep 30, 2018 | $317.9K | Jan 7, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($196.3K) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($36.7K) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($15.4K) | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | ($147.5K) | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $299.3K | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | ($199.5K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $34.9K | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | $79.7K | Jan 7, 2020 |
| FY2020 | Dec 31, 2018 | $174.3K | Apr 2, 2021 |
| FY2019 | Sep 30, 2018 | ($140.4K) | Jan 7, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.1K | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $32.0K | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $58.5K | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $687.5K | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $761.1K | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | $998.1K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $932.1K | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | $1.07M | Jan 7, 2020 |
| FY2019 | Sep 30, 2018 | $1.48M | Jan 7, 2020 |
| FY2018 | Sep 30, 2017 | $548.3K | Dec 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $326.9K | Jul 24, 2025 |
| FY2024 | Dec 31, 2023 | $315.5K | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | $201.1K | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | $117.4K | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | $312.2K | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | $133.9K | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | $195.8K | Jan 7, 2020 |
| FY2019 | Sep 30, 2018 | $240.7K | Jan 7, 2020 |
| FY2018 | Sep 30, 2017 | $37.0K | Dec 28, 2018 |
| FY2017 | Sep 30, 2016 | $17.3K | Jan 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($387.0K) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($295.0K) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($257.0K) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $486.4K | Jul 24, 2025 |
| FY2023 | Dec 31, 2021 | $643.7K | Jul 18, 2025 |
| FY2022 | Dec 31, 2020 | $685.9K | Jul 21, 2023 |
| FY2021 | Dec 31, 2019 | $798.2K | Apr 15, 2022 |
| FY2020 | Sep 30, 2019 | $873.7K | Apr 2, 2021 |
| FY2020 | Dec 31, 2018 | $1.17M | Apr 2, 2021 |
| FY2020 | Sep 30, 2018 | $1.24M | Apr 2, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.76M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($32.66M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($32.62M) | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | ($23.81M) | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | ($7.94M) | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | ($238.7K) | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | ($121.2K) | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | ($45.3K) | Jan 7, 2020 |
| FY2019 | Sep 30, 2018 | $325.4K | Jan 7, 2020 |
| FY2018 | Sep 30, 2017 | ($94.2K) | Dec 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $18.1K | Apr 2, 2021 |
| FY2020 | Dec 31, 2019 | $911 | Apr 2, 2021 |
| FY2020 | Sep 30, 2019 | $1.5K | Apr 2, 2021 |
| FY2020 | Dec 31, 2018 | $37.6K | Apr 2, 2021 |
| FY2020 | Sep 30, 2018 | $1.1K | Apr 2, 2021 |
| FY2019 | Sep 30, 2017 | $36.8K | Jan 7, 2020 |
| FY2018 | Sep 30, 2016 | $2.5K | Dec 28, 2018 |
| FY2017 | Sep 30, 2015 | $27.3K | Jan 16, 2018 |
| FY2016 | Sep 30, 2014 | $3.9K | Dec 16, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Jul 18, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 60.04M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 60.04M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | 60.04M | Jul 24, 2025 |
| FY2023 | Dec 31, 2022 | 60.04M | Jul 18, 2025 |
| FY2022 | Dec 31, 2021 | 60.04M | Jul 21, 2023 |
| FY2021 | Dec 31, 2020 | 47.76M | Apr 15, 2022 |
| FY2020 | Dec 31, 2019 | 47.76M | Apr 2, 2021 |
| FY2019 | Sep 30, 2019 | 47.76M | Jan 7, 2020 |
| FY2019 | Sep 30, 2018 | 47.76M | Jan 7, 2020 |
| FY2018 | Sep 30, 2017 | 47.66M | Dec 28, 2018 |